I’m excited to share that I’ve joined the board of 23Strands, an incredible health-tech company reshaping the future of precision medicine with a strong focus on female health.
What drew me to 23Strands is their vision to make genomics and data-driven insights accessible and actionable for everyone. They’re doing remarkable work in unlocking the potential of DNA to help people better understand their health, make informed decisions, and ultimately live longer, healthier lives.
One area that particularly inspires me is their work in women’s health using genomics to tackle issues like fertility, hormonal health, and the unique biological factors that have too often been overlooked in research. Their platform, Fertility23, integrates DNA analysis and clinical data to help identify causes of infertility and personalise care pathways. It’s science and compassion coming together and it has the power to change lives.
For too long, women’s health has been under-represented in medical innovation. What 23Strands is doing feels like a turning point, moving from reactive to proactive care, where every woman can access insights tailored to her biology and life stage.
I’m genuinely excited to contribute to this next phase of growth, supporting the team as they expand research, partnerships, and impact. The future of healthcare is personalised, predictive, and inclusive. And 23Strands is leading the way.
